During the last session, Aquestive Therapeutics, Inc. (NASDAQ:AQST)’s traded shares were 1,587,920, with the beta value of the company hitting 0. At the end of the trading day, the stock’s price was $4.73, reflecting an intraday loss of -4.64% or -$0.23. The 52-week high for the AQST share is $9.465, that puts it down -100.11% from that peak though still a striking +57.29% gain since the share price plummeted to a 52-week low of $2.02. The company’s market capitalization is $171.29 Million, and the average intraday trading volume over the past 10 days was 1.52 Million shares, and the average trade volume was 981.13 Million shares over the past three months.
Aquestive Therapeutics, Inc. (AQST) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.8. AQST has a Sell rating from none of the analyst(s) out of 6 analysts who have looked at this stock. Neither of the analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 6 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.43.
Aquestive Therapeutics, Inc. (NASDAQ:AQST): Trading Information
Aquestive Therapeutics, Inc. (AQST) registered a -4.64% downside in the last session and has traded in the green over the past 5 sessions. The stock spiked 12.89% in intraday trading to $5.43- this Wednesday, Mar 31, hitting a weekly high. The stock’s 5-day price performance is 5.35%, and it has moved by 7.26% in 30 days. Based on these gigs, the overall price performance for the year is -11.59%. The short interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) is 2.45 Million shares and it means that shorts have 0 day(s) to cover.
The consensus price target of analysts on Wall Street is $14.67, which implies an increase of 210.15% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $30 respectively. As a result, AQST is trading at a discount of 534.25% off the target high and 47.99% off the low.
Aquestive Therapeutics, Inc. (AQST) projections and forecasts
Statistics show that Aquestive Therapeutics, Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Aquestive Therapeutics, Inc. (AQST) shares have jump down -1.87% during the last six months, with a year-to-date growth rate less than the industry average at 6.02% against 17.2%. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 12.2% this quarter and then fall -514.3% in the quarter after that. In the rating firms’ projections, revenue will decline -14.7% compared to the previous financial year.
Revenue for the current quarter is expected to be $8.97 Million as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $9.82 Million by the end of June 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarter totaled $8.77 Million. In this case, analysts expect current quarter sales to grow by 2.3%.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated -14.3%. While earnings are projected to return 36.6% in 2021, the next five years will return 0% per annum.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Aquestive Therapeutics, Inc. (NASDAQ:AQST)’s Biggest Investors
Aquestive Therapeutics, Inc. insiders own 6.14% of total outstanding shares while institutional holders control 53.23%, with the float percentage being 56.71%. Bratton Capital Management, LP is the largest shareholder of the company, while 96 institutions own stock in it. As of Dec 30, 2020, the company held over 11.5 Million shares (or 33.28% of all shares), a total value of $61.54 Million in shares.
The next largest institutional holding, with 1.39 Million shares, is of Perceptive Advisors Llc’s that is approximately 4.01% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $7.41 Million.
Also, the Mutual Funds coming in first place with the largest holdings of Aquestive Therapeutics, Inc. (AQST) shares are iShares Russell 2000 ETF and TIAA-CREF Funds-Quant Small Cap Equity Fund. Data provided on Feb 27, 2021 indicates that iShares Russell 2000 ETF owns about 462,879 shares. This amounts to just over 1.34 percent of the company’s overall shares, with a $2.12 Million market value. The same data shows that the other fund manager holds slightly less at 443.48 Thousand, or about 1.28% of the stock, which is worth about $2.35 Million.